Share This

Related Topics News -

     
 Title only   |   Print 
     
《大行》高盛升翰森製藥目標價至17.91元 下調盈測反映較高研發開支

2024-05-02T  
翰森製藥與荃信生物-B簽訂QX004N對外授權協議 首付款7,500萬人幣

2024-04-25T  
翰森製藥新藥「HS-10504片」臨床試驗獲批

2024-04-04T  
《大行報告》匯豐研究微升翰森製藥目標價至18.6元 創新平台領先足跡遍佈全球

2024-04-03T  
《大行報告》花旗升翰森製藥目標價至28元 目標今年銷售雙位數增長

2024-03-28T  
《大行報告》交銀國際升翰森製藥目標價至16元 業績超預期

2024-03-28T  
《大行報告》中金升翰森製藥目標價27.2%至17.81元 創新藥收入佔比提升

2024-03-28T  
恆指跌幅擴至逾200點曾失16,400 翰森及華潤萬象逆市升4%-6%

2024-03-27T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.